Loading page
Loading page
Loading substance route
5-APB is encountered as succinate and hydrochloride salt forms. The hydrochloride variant demonstrates approximately 10% greater potency by mass and requires proportional dose reduction.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Moderate abuse potential with high potential for compulsive use and capacity for psychological dependence. When addiction develops, cravings and withdrawal effects may occur upon cessation. Compulsive redosing has been reported as a notable effect.
The exact toxic dosage is unknown due to limited human usage history. Deaths have been reported both in combination with other drugs and from 5-APB use alone.
Long-term use may carry risk of cardiotoxicity based on the substance's potent 5-HT2B receptor agonism; this risk is inferred from similar compounds like fenfluramine and MDMA rather than direct studies on 5-APB itself.
Abuse of amphetamine-class compounds at high doses for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Approximately 5-15% of users who develop stimulant psychosis may fail to recover completely. Acute symptoms typically respond to antipsychotic treatment.
The development of 5-APB emerged from research into benzofuran-based entactogens during the 1990s. Medicinal chemist David E. Nichols and colleagues at Purdue University conducted foundational work on benzofuran analogues, examining the role of the MDA dioxole ring structure in interacting with…
Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under Brazilian drug control legislation.
Controlled under Anlage II of the Betäubungsmittelgesetz (Narcotics Act, Schedule II) since July 17, 2013. Manufacturing, possession, import, export, purchase, sale, procurement, or dispensing without a license is illegal.
Currently unscheduled, though it belongs to a substance group that may be prohibited under recently passed New Psychoactive Substances (NPS) legislation.
Initially classified as a Temporary Class Drug on June 10, 2013. Made a permanent Class B, Schedule 1 substance on June 10, 2014 alongside all other benzofuran entactogens and structurally related compounds.
Classified as a narcotic substance since May 9, 2018, alongside other benzofuran-derived compounds.
Designated as a controlled substance effective September 16, 2015.
Specifically named as a controlled substance under Verzeichnis E of Swiss drug control legislation.
Not specifically scheduled at the federal level. However, due to structural similarity to MDA, it may be prosecuted under the Federal Analogue Act if sold or possessed with intent for human consumption.
13 sources cited